Randomized Controlled Multicenter Trial of Aerosolized Ribavirin for Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients | Zendy

Michael Boeckh | Zendy; Janet A. Englund | Zendy; Y. Li | Zendy; Christina R. Miller | Zendy; Alan S. Cross | Zendy; H. Fernández | Zendy; Jane Kuypers | Zendy; H. Kim | Zendy; J. W. Gnann | Zendy; Richard J. Whitley | Zendy

Open Access

Randomized Controlled Multicenter Trial of Aerosolized Ribavirin for Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients

Author(s) -

Michael Boeckh,

Janet A. Englund,

Y. Li,

Christina R. Miller,

Alan S. Cross,

H. Fernández,

Jane Kuypers,

H. Kim,

J. W. Gnann,

Richard J. Whitley

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/509930

Subject(s) - ribavirin , medicine , pneumonia , adverse effect , viral load , randomized controlled trial , lower respiratory tract infection , viral pneumonia , immunology , respiratory tract infections , respiratory system , virus , disease , hepatitis c virus , covid-19 , infectious disease (medical specialty)

Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic cell transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research